Standard BioTools Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026 with the Securities and Exchange Commission on November 3, 2026.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $267,487 thousand as of September 30, 2026, up from $120,863 thousand at December 31, 2025.
  • Short-term investments: Short-term investments totaled $193,624 thousand as of September 30, 2026, compared to $66,712 thousand at December 31, 2025.
  • Shares outstanding: As of November 1, 2026, the company reported 394,790,441 shares of common stock outstanding, $0.001 par value per share.
  • Assets held for sale: Current assets held for sale were $0 as of September 30, 2026, down from $228,406 thousand at December 31, 2025, according to the filing.
  • Accounts receivable: Accounts receivable, net, were $12,982 thousand at September 30, 2026, compared to $13,431 thousand at December 31, 2025.
  • Inventory: Inventory was reported at $17,617 thousand at September 30, 2026, versus $19,981 thousand at December 31, 2025.

Standard BioTools Balance Sheet and Key Disclosures for the Quarter Ended September 30, 2026

Standard BioTools Inc. (NASDAQ:LAB), headquartered at 50 Milk Street, 10th Floor, Boston, MA 02109, filed its Form 10-Q for the quarterly period ended September 30, 2026. According to the filing, the company is classified as an accelerated filer and is incorporated in Delaware, with an I.R.S. Employer Identification Number of 77-0513190.

The condensed consolidated balance sheet disclosed in the filing shows total current assets of $497,302 thousand as of September 30, 2026, compared to $454,264 thousand at December 31, 2025. The company reported that current assets held for sale dropped from $228,406 thousand at year-end 2025 to zero by September 30, 2026, which the filing attributes to dispositions including those of the mass cytometry and microfluidics businesses. The filing references transactions with Illumina, Inc. and a pending transaction with Treeline Biosciences, Inc. among the activities covered in its forward-looking disclosures.

The filing notes that it contains forward-looking statements, which the company identifies as subject to known and unknown risks and uncertainties, and cautions that "actual future results may be materially different from what we expect." These statements are the company's own and are subject to its cautionary language as described in the filing. The company stated it assumes no obligation to update forward-looking statements except as required by law.

What Was Disclosed

Standard BioTools filed its unaudited Form 10-Q for the quarter ended September 30, 2026, disclosing condensed consolidated balance sheet data, share count, filer status, and forward-looking risk factors, including pending and completed transactions affecting its asset base.